• A thalidomide analog that inhibits TNF-α production, stimulates T cells, reduces serum levels of the cytokines, VEGF, and bFGF, and inhibits angiogenesis
    • Also promotes G1 cell cycle arrest and apoptosis of malignant cells
    • FDA approved for MM, 5q-MDS, and MCL
    • Recommended dose: 25 mg once daily (MM and MCL); 10 mg PO daily (MDS)
    • Half-life: 3 to 5 hours
    • Metabolism: P-glycoprotein substrate
    • Common side effects: Bone marrow suppression (US box warning), thromboembolic events (US box warning), fatigue, weakness, constipation, nausea/vomiting, diarrhea, muscle cramp, pyrexia, rash (pruritus), upper respiratory infection
    • Clinical pearls:
    Other topics in Targeted and Immunotherapy Agents